This phase I study defined the following two MTDs for clofarabine given as a 1-hour infusion daily for 5 days: 2 mg/m(2) for solid tumors, the DLT being myelosuppression; and 40 mg/m(2) for acute leukemia, the DLT being hepatotoxicity. Encouraging activity was observed in acute leukemia.
No takes yet. Share an insight, caveat, or question.
Kantarjian et al. (2003) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: